MYRIAD GENETICS, INC. Cumulative Effect on Retained Earnings, Tax (Deprecated 2020-01-31)
MYRIAD GENETICS, INC. (MYGN) reported Cumulative Effect on Retained Earnings, Tax (Deprecated 2020-01-31) of $0 for the 12-month period ending 2019-06-30, per its 10-K filed 2019-08-13.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsTax1 · last filed 2019-08-13
- MYRIAD GENETICS, INC. cumulative effect on retained earnings, tax (deprecated 2020-01-31) for fiscal 2019 was $0.00.
- MYRIAD GENETICS, INC. cumulative effect on retained earnings, tax (deprecated 2020-01-31) for fiscal 2018 was $0.00.
- MYRIAD GENETICS, INC. cumulative effect on retained earnings, tax (deprecated 2020-01-31) for fiscal 2017 was $0.00.
- MYRIAD GENETICS, INC. cumulative effect on retained earnings, tax (deprecated 2020-01-31) for fiscal 2016 was $0.00.
| Period end | Cumulative Effect on Retained Earnings, Tax (Deprecated 2020-01-31) 12 month |
|---|---|
| 2019-06-30 | $0.00 10-K · filed 2019-08-13 |
| 2018-06-30 | $0.00 10-K · filed 2018-08-24 |
| 2017-06-30 | $0.00 10-K · filed 2017-08-09 |
| 2016-06-30 | $0.00 10-K · filed 2016-08-10 |
| 2015-06-30 | $0.00 10-K · filed 2015-08-12 |
| 2014-06-30 | $0.00 10-K · filed 2014-08-13 |
| 2013-06-30 | $0.00 10-K · filed 2013-08-14 |
| 2012-06-30 | $0.00 10-K · filed 2012-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |